Dexcom Inc 2026: Revenue $1.31B, EPS $0.64— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Dexcom Inc reported Q2 2026 results with revenue of $1.31B, up 13.1% YoY, and diluted EPS of $0.64, up 42.2%. Net income reached $249.1M. Growth was driven by higher disposable sensor volume and favorable revenue per customer. Gross margin improved to 63%, supported by manufacturing efficiencies and product momentum from G7 15 Day and Stelo OTC biosensors.
Dexcom Inc reported second-quarter 2026 results with revenue of $1.31B, net income of $249.1M and diluted EPS of $0.64, all ahead of the prior-year quarter as the company continued to expand its customer base and improve margins.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $1.31B | $1.16B | 13.1% |
| Net income² | $249.1M | $179.8M | 38.5% |
| Diluted EPS³ | $0.64 | $0.45 | 42.2% |
¹ Reported as “Revenue”. ² Reported as “Net income”. ³ Reported as “Diluted net income per share”.
Business Highlights
- Revenue grew 13% year over year to $1.31B, driven by higher disposable sensor volume and favorable revenue per customer.
- The distributor channel remained the primary sales route, accounting for roughly 84% of Q2 revenue, while direct international sales expanded.
- Product momentum continued with the G7 15 Day (launched 2025) and the Stelo OTC biosensor (Aug 2024), broadening consumer and prediabetes reach.
- Gross margin improved to 63%, aided by higher volumes, benefits from G7 15 Day and manufacturing efficiencies despite costs related to phasing out G6.
- Worldwide customer growth remained strong, with substantial net additions in the prior year period that increased utilization and improved payor mix.
Original SEC Filing: DEXCOM INC [ DXCM ] - 10-Q - Jul. 30, 2026